Clinical Trials
114 trialsCAR-T Followed by Bispecific Antibodies
Abramson Cancer Center at Penn Medicine
SPiReL
Sunnybrook Health Sciences Centre
Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
Ruijin Hospital
Pembrolizumab in Neoplasms or Lymphomas
Dana-Farber Cancer Institute
Study of Purinostat Mesylate for Injection in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Chengdu Zenitar Biomedical Technology Co., Ltd
Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+
Virginia Commonwealth University
DALY II Japan
Miltenyi Biomedicine GmbH
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
Ruijin Hospital
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Pirtobrutinib, Lisaftoclax, and Rituximab in the Treatment of R/R DLBCL
The First Affiliated Hospital of Soochow University
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Sun Yat-sen University
BEB
Insel Gruppe AG, University Hospital Bern
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Institute of Hematology & Blood Diseases Hospital, China
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Masonic Cancer Center, University of Minnesota
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
The First Affiliated Hospital with Nanjing Medical University
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
The First Affiliated Hospital of Xiamen University
AZA Combined With RCHOP in P53-mutated DLBCL.
The First Affiliated Hospital of Xiamen University
Dragon
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
HOVON161
University Medical Center Groningen
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
Zhejiang Provincial People's Hospital
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Australasian Leukaemia and Lymphoma Group
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Relyage
Centre Hospitalier Universitaire, Amiens
DLBCL
Rush University Medical Center
Monoclonal Antibody Therapy in Treating Patients With Lymphoproliferative Disorder Associated With Immunosuppression Therapy
Stanford University
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Masonic Cancer Center, University of Minnesota
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
Masonic Cancer Center, University of Minnesota
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Fred Hutchinson Cancer Center
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Roswell Park Cancer Institute
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis
Lymphoma Study Association
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
Fred Hutchinson Cancer Center
Treg Cells for AGVHD in Non-myeloablative UCB Transplant
Masonic Cancer Center, University of Minnesota
Rituximab and Combination Chemotherapy With or Without Bleomycin Sulfate in Treating Patients With Primary Mediastinal Large B-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Children's Oncology Group
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
OHSU Knight Cancer Institute
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Fred Hutchinson Cancer Center
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center